The share of patents with DM2 according to process quality indicators before and after the introduction of model practices_
| Quality indicators | Before model practices No (%) | After model practices No (%) | X2 | P |
|---|---|---|---|---|
| Measured HbA1c | 33 (25) | 108 (82) | 43.32 | <0.01 |
| Laboratory tests if all lab tests (except HbA1c) were performed at least once per year (creatinine, oGFR, serum lipids, urine dip-sticks, serum glucose) | 51 (39) | 99 (75) | 40.50 | <0.01 |
| Foot exam | 9 (7) | 90 (68) | 75.00 | <0.01 |
| Eye exam | 59 (45) | 120 (91) | 51.57 | <0.01 |
| Measured blood pressure | 117 (89) | 125 (95) | 3.030 | n.s. |
| Annual examination | 59 (45) | 119 (90) | 49.73 | <0.01 |
HbA1c levels in DM2 patients before and after the introduction of model practices (N=33)_
| HbA1c (%) before model practices | HbA1c (%) after model practices | t(df) | P | ||
|---|---|---|---|---|---|
| M | SD | M | SD | ||
| 7.60 | 1.32 | 7.33 | 1.21 | 1.08(33) | n.s. |